Phathom Pharmaceuticals (PHAT) Capital Expenditures (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Capital Expenditures of $171000.0 for Q1 2026, up 288.64% year-over-year from $44000.0 in Q1 2025, and down 84.2% quarter-over-quarter from $1.1 million in Q4 2025.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Capital Expenditures (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Capital Expenditures for 8 consecutive years, with $171000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures rose 288.64% year-over-year to $171000.0; the TTM figure through Jun 2026 stood at $1.3 million (up 680.49% YoY), while the FY2025 annual figure was $1.2 million, up 806.67% from the prior year.
- Capital Expenditures eased to $171000.0 in Q1 2026 per PHAT's latest filing, from $1.1 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.2 million in Q3 2023 and bottomed at -$1.8 million in Q4 2023.
- Historically, Capital Expenditures has averaged $247352.9 across 5 years, with a median of $71000.0 in 2025.
- Annual changes were most pronounced in 2023 — Capital Expenditures tumbled 540.78% — and 2025, when it soared 21540.0%.
- Phathom Pharmaceuticals' Capital Expenditures stood at $412000.0 in 2022, then sank by 540.78% to -$1.8 million in 2023, then jumped by 100.28% to $5000.0 in 2024, then jumped by 21540.0% to $1.1 million in 2025, then tumbled by 84.2% to $171000.0 in 2026.
- Business Quant data shows PHAT's Capital Expenditures at $171000.0 in Q1 2026, $1.1 million in Q4 2025, and $27000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 171,000.00 |
| Dec 31, 2025 | 1.08 Mn |
| Sep 30, 2025 | 27,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 44,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 46,000.00 |
| Mar 31, 2024 | 40,000.00 |
| Dec 31, 2023 | -1.82 Mn |
| Sep 30, 2023 | 3.23 Mn |
| Jun 30, 2023 | 6,000.00 |
| Mar 31, 2023 | 214,000.00 |
| Dec 31, 2022 | 412,000.00 |
| Sep 30, 2022 | 134,000.00 |
| Jun 30, 2022 | 375,000.00 |
| Mar 31, 2022 | 120,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Sep 30, 2021 | 14,000.00 |
| Jun 30, 2021 | 45,000.00 |